The improved version of the text is: “Flunil” (Note: Since “Flunil” is a proper noun/brand name, it remains unchanged in translation. The improved version simply presents it in a cleaner format with proper capitalization.)

Product Overview

Flunil is a pharmaceutical preparation containing Fluoxetine as its active component. As a selective serotonin reuptake inhibitor (SSRI), it is clinically indicated for managing major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. The therapeutic action involves enhancing serotonin availability in synaptic clefts, thereby regulating mood, appetite, sleep patterns, and energy metabolism. The drug is formulated in multiple dosage forms including immediate-release tablets, capsules, and oral solution, with standard administration being once daily.

Therapeutic Indications

Flunil is indicated for:

• Major Depressive Disorder (MDD): Management of persistent depressive symptoms including anhedonia, psychomotor retardation, and cognitive impairment
• Obsessive-Compulsive Disorder: Reduction of intrusive thoughts and compulsive rituals
• Bulimia Nervosa: Decrease in binge-purge cycle frequency
• Panic Disorder: Prevention of acute panic episodes with associated autonomic symptoms

Administration Guidelines

For optimal therapeutic outcomes:

1. Administer precisely as prescribed, maintaining consistent dosing schedule
2. Standard dosing frequency is once daily (morning or evening), with food tolerance being patient-specific
3. Swallow solid dosage forms intact with adequate water
4. For liquid formulation, use calibrated measuring device for accurate dosing
5. Therapeutic response may require 2-4 weeks of continuous therapy

Mechanism of Action

Fluoxetine exerts its pharmacodynamic effects through:

• Selective inhibition of serotonin transporter (SERT) proteins
• Increased extracellular serotonin concentrations in CNS synapses
• Downstream modulation of 5-HT receptor sensitivity
• Neuroplastic changes in limbic system pathways

Dosage Protocol

Therapeutic dosing requires:

• Initial titration based on indication and patient characteristics
• Maintenance dosing adjusted according to therapeutic response
• Minimum 4-6 week trial period for efficacy assessment
• Gradual tapering when discontinuing therapy (over ≥2 weeks)

Therapeutic Advantages

1. Established efficacy in multiple neuropsychiatric conditions
2. Favorable pharmacokinetic profile allowing once-daily dosing
3. Multiple formulation options for personalized therapy
4. Demonstrated long-term safety profile
5. Positive impact on quality of life measures

Adverse Effect Profile

Common treatment-emergent effects include:

• Gastrointestinal: Nausea (15-20%), diarrhea (8%)
• Neurological: Headache (20%), insomnia (10-15%)
• Autonomic: Dry mouth (10%), sweating (7%)
• Sexual: Libido changes (5-10%), orgasmic dysfunction

Important Safety Considerations

Critical prescribing information:

• Boxed Warning: Increased suicidality risk in pediatric and young adult populations
• Contraindicated with MAOIs (require 5-week washout period)
• Potential for serotonin syndrome with serotonergic agents
• Caution in hepatic impairment (consider dose reduction)
• Monitor for activation syndrome during initial treatment

Storage Requirements

Proper medication storage entails:

• Maintaining at controlled room temperature (20-25°C)
• Protecting from moisture and light exposure
• Securing in child-resistant packaging
• Proper disposal of expired medication

Medical Disclaimer

This information serves educational purposes only and does not constitute medical advice. The content:

• Represents general drug information
• Does not replace professional clinical judgment
• May not include all potential interactions or contraindications
• Should be reviewed with prescribing healthcare provider

Always consult qualified medical professionals for personalized treatment recommendations and medication management.